INNATE PHARMA TO PARTICIPATE IN THE CITI 2018 EUROPEAN HEALTHCARE CONFERENCE ON JUNE 20, 2018

Marseille, France, June 18, 2018, 07:00 AM CEST

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the Citi 2018 European Healthcare Conference on June 20, 2018, in London.

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (http://www.innate-pharma.com/en/investors).

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the body’s own immune system.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.

The Company’s broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.

Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

| ISIN code | FR0010331421 |
| Ticker code | IPH |
| LEI | 9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

**Investors**

**Innate Pharma**

Dr Markus Metzger / Jérôme Marino
Investor relations
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com

**International Media**

**Consilium Strategic Communications**

Mary-Jane Elliott / Jessica Hodgson / Melissa Gardiner
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com

**French Media**

**ATCG Press**

Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com